Melissa McCracken

Dr. McCracken is a Partner at Nextech, which she joined in 2019. She is a scientist by training and has a passion for emerging technologies in cancer therapies. Dr. McCracken is a board member of TYRA Biosciences and Ambagon Therapeutics, board observer of IconOVir Bio, and a previous board member of ImaginAb and board observer of Silverback Therapeutics. Prior to Nextech, Dr. McCracken was at Third Rock Ventures where she helped build and launch Celsius Therapeutics, a company focused on discovering precision therapeutics for oncology and autoimmune. Dr. McCracken completed a postdoctoral fellowship at Stanford University where her research focused on immuno-oncology. She holds a PhD in molecular and medical pharmacology from University of California and a BS in biochemistry and molecular biology from University of California.